Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
37192724
DOI
10.1016/j.jvir.2023.05.017
PII: S1051-0443(23)00349-4
Knihovny.cz E-zdroje
- MeSH
- Aspirin škodlivé účinky MeSH
- cévní mozková příhoda * diagnostické zobrazování terapie MeSH
- intrakraniální krvácení chemicky indukované MeSH
- ischemická cévní mozková příhoda * diagnostické zobrazování terapie MeSH
- ischemie mozku * diagnostické zobrazování terapie MeSH
- klopidogrel škodlivé účinky MeSH
- lidé MeSH
- mechanická trombolýza * škodlivé účinky MeSH
- trombektomie škodlivé účinky MeSH
- trombolytická terapie škodlivé účinky MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- Aspirin MeSH
- klopidogrel MeSH
PURPOSE: To investigate the safety and efficacy of baseline antiplatelet treatment in patients with acute ischemic stroke (AIS) undergoing mechanical thrombectomy (MT). MATERIALS AND METHODS: Baseline use of antiplatelet medication before MT for (AIS) may provide benefit on reperfusion and clinical outcome but could also carry an increased risk of intracranial hemorrhage (ICH). All consecutive patients with AIS and treated with MT with and without intravenous thrombolysis (IVT) between January 2012 and December 2019 in all centers performing MT nationwide were reviewed. Data were prospectively collected in national registries (eg, SITS-TBY and RES-Q). Primary outcome was functional independence (modified Rankin Scale 0-2) at 3 months; secondary outcome was ICH. RESULTS: Of the 4,351 patients who underwent MT, 1,750 (40%) and 666 (15%) were excluded owing to missing data from the functional independence and ICH outcome cohorts, respectively. In the functional independence cohort (n = 2,601), 771 (30%) patients received antiplatelets before MT. Favorable outcome did not differ in any antiplatelet, aspirin, and clopidogrel groups when compared with that in the no-antiplatelet group: odds ratio (OR), 1.00 (95% CI, 0.84-1.20); OR, 1.05 (95% CI, 0.86-1.27); and OR, 0.88 (95% CI, 0.55-1.41), respectively. In the ICH cohort (n = 3,685), 1095 (30%) patients received antiplatelets before MT. The rates of ICH did not increase in any treatment options (any antiplatelet, aspirin, clopidogrel, and dual antiplatelet groups) when compared with those in the no-antiplatelet group: OR, 1.03 (95% CI, 0.87-1.21); OR, 0.99 (95% CI, 0.83-1.18); OR, 1.10 (95% CI, 0.82-1.47); and OR, 1.43 (95% CI, 0.87-2.33), respectively. CONCLUSIONS: Antiplatelet monotherapy before MT did not improve functional independence or increase the risk of ICH.
Center for Health Research Medical Faculty Ostrava University Ostrava Czech Republic
Department of Neurology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Department of Neurology Hospital Ceske Budejovice Ceske Budejovice Czech Republic
Department of Neurology Na Homolce Hospital Prague Czech Republic
Department of Radiology Palacky University Medical School and Hospital Olomouc Czech Republic
Neurocentre Regional Hospital Liberec Liberec Czech Republic
Citace poskytuje Crossref.org
